Greenwich Lifesciences Inc (GLSI) - Net Assets
Based on the latest financial reports, Greenwich Lifesciences Inc (GLSI) has net assets worth $2.18 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.81 Million) and total liabilities ($1.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read how much debt does Greenwich Lifesciences Inc carry for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.18 Million |
| % of Total Assets | 57.39% |
| Annual Growth Rate | N/A |
| 5-Year Change | -90.83% |
| 10-Year Change | N/A |
| Growth Volatility | 22.72 |
Greenwich Lifesciences Inc - Net Assets Trend (2017–2024)
This chart illustrates how Greenwich Lifesciences Inc's net assets have evolved over time, based on quarterly financial data. Also explore Greenwich Lifesciences Inc total assets for the complete picture of this company's asset base.
Annual Net Assets for Greenwich Lifesciences Inc (2017–2024)
The table below shows the annual net assets of Greenwich Lifesciences Inc from 2017 to 2024. For live valuation and market cap data, see Greenwich Lifesciences Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $2.53 Million | -62.18% |
| 2023-12-31 | $6.70 Million | -49.29% |
| 2022-12-31 | $13.21 Million | -50.75% |
| 2021-12-31 | $26.83 Million | -2.89% |
| 2020-12-31 | $27.63 Million | +2146.12% |
| 2019-12-31 | $-1.35 Million | +86.66% |
| 2018-12-31 | $-10.12 Million | -18.64% |
| 2017-12-31 | $-8.53 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Greenwich Lifesciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4405434900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $13.15K | 0.52% |
| Other Components | $68.67 Million | 2710.07% |
| Total Equity | $2.53 Million | 100.00% |
Greenwich Lifesciences Inc Competitors by Market Cap
The table below lists competitors of Greenwich Lifesciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Favite Inc
TW:3535
|
$320.04 Million |
|
RoadMain T Co Ltd
SHG:603860
|
$320.04 Million |
|
Pengana Private Equity Trust
AU:PE1
|
$320.11 Million |
|
Tianyu Ecology & Landscape Co
SHG:603717
|
$320.13 Million |
|
Bank of Greece
AT:TELL
|
$319.82 Million |
|
Borosil Limited
NSE:BOROLTD
|
$319.62 Million |
|
Orient Cement Limited
NSE:ORIENTCEM
|
$319.52 Million |
|
Campine
BR:CAMB
|
$319.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Greenwich Lifesciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,700,409 to 2,534,036, a change of -4,166,373 (-62.2%).
- Net loss of 15,788,809 reduced equity.
- New share issuances of 4,369,109 increased equity.
- Other factors increased equity by 7,253,327.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-15.79 Million | -623.07% |
| Share Issuances | $4.37 Million | +172.42% |
| Other Changes | $7.25 Million | +286.24% |
| Total Change | $- | -62.18% |
Book Value vs Market Value Analysis
This analysis compares Greenwich Lifesciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 121.72x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-0.73 | $23.70 | x |
| 2018-12-31 | $-0.85 | $23.70 | x |
| 2019-12-31 | $-0.11 | $23.70 | x |
| 2020-12-31 | $2.18 | $23.70 | x |
| 2021-12-31 | $2.07 | $23.70 | x |
| 2022-12-31 | $1.02 | $23.70 | x |
| 2023-12-31 | $0.52 | $23.70 | x |
| 2024-12-31 | $0.19 | $23.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Greenwich Lifesciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -623.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.62x
- Recent ROE (-623.07%) is below the historical average (-104.85%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-720.43K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-677.65K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.29 Million |
| 2020 | -6.74% | 0.00% | 0.00x | 1.04x | $-4.63 Million |
| 2021 | -17.03% | 0.00% | 0.00x | 1.01x | $-7.25 Million |
| 2022 | -59.22% | 0.00% | 0.00x | 1.02x | $-9.15 Million |
| 2023 | -132.71% | 0.00% | 0.00x | 1.04x | $-9.56 Million |
| 2024 | -623.07% | 0.00% | 0.00x | 1.62x | $-16.04 Million |
Industry Comparison
This section compares Greenwich Lifesciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Greenwich Lifesciences Inc (GLSI) | $2.18 Million | 0.00% | 0.74x | $319.90 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also de… Read more